Debatforum

Morningstar og FastGraphs og mange andre spytter anbefalinger ud i en lind stroem lige for tiden. Jeg har allerede delt mange af dem herinde. Der er kommet nye til. Jeg samler dem her. Jeg har selv nogle af dem i min portefoelje. Jeg henter en stor del af min inspiration fra Morningstar, som er den eneste service jeg abonnerer paa. Buying Opportunity in Multiple Sectors as Market Weighs Short-Term Impact https://www.morningstar.com/articles/974333/article 17 Stocks With Fortress Balance Sheets These sturdy companies can withstand the economic slowdown--and they're on sale, too. https://www.morningstar.com/articles/973993/17-stocks-with-fortress-balance-sheets 16 Solid Stocks During Rocky Times https://www.morningstar.com/articles/972455/16-solid-stocks-during-rocky-times It's a Buyers' Market Choose Quality If You're Scared: 20 A Rated Low Debt Blue Chips to Consider https://www.youtube.com/watch?v=kQXqDZ_U9qA 10 High Quality A Rated Blue Chips with Low Debt to Buy Today https://www.youtube.com/watch?v=bZ3H33pGnAg Three Stocks to Look at in This Market Right Now https://www.youtube.com/watch?v=B-pCjuTWf6o Top 10 Dividend Aristocrats to Buy In This Crazy Market https://www.youtube.com/watch?v=nzr3qKXZgEU Den her video fra <a href="/investors/32958/Markettimer" class="regular_link">Markettimer</a> <a class="username_plus_icon" title="Denne bruger har Plus" href="donation"><span class="inline plus12-icon"></span></a> / Building Freedom, hvor han screenede paa credit rating og andre parametre, kunne jeg godt lide: https://www.youtube.com/watch?v=tZiOefJTm-o [image: 83292_11401.jpg] [image: 83292_11413.png]

Til de af jer, der er fokuseret på udbytte-investeringer, så har jeg her lavet en lille engelsk video om, hvad jeg er bekymret for på udbytteområdet. Hvis du er en erfaring udbytteinvestor, så ved du sikkert allerede dette, men der vil komme mange nedsættelser eller annulleringer af udbytter i den kommende tid, og det kan godt gøre udbytteinvestering til lidt et minefelt. https://www.youtube.com/watch?v=iWe3fAnDfyE

17 Stocks With Fortress Balance Sheets https://www.morningstar.com/articles/973993/17-stocks-with-fortress-balance-sheets These sturdy companies can withstand the economic slowdown--and they're on sale, too. https://www.midgardfinance.com/tabulate/17-stocks-with-fortress-balance-sheets.htm [image: 83281_11401.jpg]

Jeg opretter endnu en Corona virus tråd, for at undgå at links til vigtigt læsestof forsvinder nede i en lang trådstruktur. Først den vigtigste. En artikel om strategier om epidemibekæmpelse og dets konsekvenser: https://medium.com/@tomaspueyo/coronavirus-the-hammer-and-the-dance-be9337092b56 Inklusive et bud på hvad der virker og hvornår man kan vurdere at epidemien er under kontrol. Så en artikel om matematikken bag epidemier. Også en vigtig artikel for at kunne forstå dynamikken i den situation vi står i. Det er ren matematik, ligeså snart den slap ud fra Kina. https://www.washingtonpost.com/graphics/2020/world/corona-simulator/ God læselyst.

Er det ved at være tid til at købe?

Konsolidator har den seneste tid nægtet at gå under kurs 30, men har nogle dage lige strejfet, for så straks at gå i 32/33 igen. Jeg troede egenlig den skulle videre ned i dag, men dette viste sig ikke at være tilfældet. Den er pt. i ca. kurs 34, og jeg tror den lynhurtigt gå i 38-40 stykker, hvis der kommer et par dage med plusser. Køb før din nabo:)

NIKE, INC. REPORTS FISCAL 2020 THIRD QUARTER RESULTS https://investors.nike.com/investors/news-events-and-reports/investor-news/investor-news-details/2020/NIKE-Inc-Reports-Fiscal-2020-Third-Quarter-Results/default.aspx NIKE, Inc. (NYSE:NKE) today reported fiscal 2020 financial results for its third quarter ended February 29, 2020. Revenues rose 5 percent on a reported basis and 7 percent on a currency-neutral basis*; Digital sales up 36 percent versus prior year Diluted earnings per share was $0.53, including a $0.25 non-recurring, non-cash charge associated with the transition to a strategic distributor model in South America Inventory increased 7 percent to $5.8 billion; closeout inventory units declined versus prior year Revenues increased to $10.1 billion in the third quarter, up 5 percent on a reported basis and up 7 percent on a currency-neutral basis, driven by 13 percent currency-neutral growth in NIKE Direct with digital growth of 36 percent and strong growth across EMEA, APLA and North America, offset by the impact of COVID-19 on our business in Greater China. Digital sales in Greater China increased more than 30 percent while brick and mortar retail sales were impacted by temporary store closures related to COVID-19. "In an extraordinarily dynamic time, NIKE's strong results are testament to our deep consumer connections, compelling product innovation and agile teams around the world. We know it's in times like these that strong brands get even stronger," said John Donahoe, President and CEO, NIKE, Inc. "As we start to see recovery in China, no one is better equipped than NIKE to navigate the current climate."** Diluted earnings per share for the quarter was $0.53, including a $0.25 non-recurring, non-cash charge related to our entry into definitive agreements to transition our Brazil, Argentina, Chile and Uruguay businesses to a strategic distributor model. Diluted earnings per share was also adversely impacted by COVID-19. "As we close Q3, NIKE's Brand leadership and business momentum have been stronger than ever and unrivaled around the world," said Andy Campion, Executive Vice President and Chief Financial Officer, NIKE, Inc. "Amidst the dynamics that we are facing, we are executing against an operational playbook that will expedite NIKE's return to profitable, capital efficient growth leveraging our strong financial position, the strongest partnerships across the value chain in our industry, and our leading digital capabilities."** COVID-19 Update As discussed in our press release issued on February 4, 2020, operations in Greater China were materially impacted as a result of COVID-19. In the third quarter, on a currency-neutral basis, Greater China revenues were down 4 percent following 22 consecutive quarters of double-digit growth. However, during the first two months of the third quarter, Greater China's revenue grew strong double digits, offset by the impacts of COVID-19 beginning in late January. At the peak in February, roughly 75 percent of NIKE-owned and partner doors in Greater China were closed with others operating on reduced hours. Currently, nearly 80 percent of doors are open in Greater China with an even higher rate in key cities. Beginning March 16th, all NIKE-owned stores, outside of Greater China, Japan and Korea were closed to help curb the spread of COVID-19. Nike sales beat analysts' estimates, but earnings fall, hurt by coronavirus pandemic https://www.cnbc.com/2020/03/24/nike-nke-reports-q3-fiscal-2020-earnings.html Nike revenue beats as digital growth offsets rare China sales fall on virus hit https://www.reuters.com/article/us-nike-results/nike-revenue-beats-as-digital-growth-offsets-rare-china-sales-fall-on-virus-hit-idUSKBN21B38L Nike Rallies After Results Suggest It's Weathering Virus Era https://www.bloomberg.com/news/articles/2020-03-24/nike-sales-top-estimates-as-it-weathers-early-days-of-covid-19 8K: https://www.sec.gov/Archives/edgar/data/320187/000032018720000014/0000320187-20-000014-index.htm Footwear & Accessories https://www.midgardfinance.com/tabulate/FootwearAndAccesories.htm [image: 83239_NKE_us_gaap.RevenueFromContractWithCustomerExcludingAssessedTax_us_gaap.ProductOrService_.png] [image: 83239_us_gaap.ConsolidationItems_us_gaap.StatementBusinessSegments_us_gaap.Subsegments_us_gaap.OperatingSegments_nke.NIKEBrand.png] [image: 83239_NKE_us_gaap.RevenueFromContractWithCustomerExcludingAssessedTax_us_gaap.ContractWithCustomerSalesChannel_.png]

Updates from Lilly about insulin supply and affordability https://investor.lilly.com/news-releases/news-release-details/updates-lilly-about-insulin-supply-and-affordability To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY) today is providing updates related to insulin supply and affordability: As we announced on March 3, Lilly does not currently anticipate shortages for any of our medicines, including all forms of insulin. Lilly is committed to manufacturing medicines that meet global safety, quality, value and environmental expectations. With the help of a large network of global external manufacturing partners we supply medication to nearly 125 countries. Lilly is committed to public health and the needs of people with chronic conditions who depend on our medicines around the world. Since the initial outbreak, Lilly has closely monitored our supply chain for potential impact to the supply of our medicines around the world. We continue to monitor the situation, and our insulin manufacturing sites in the U.S. and Europe remain operational, with increased precautions in place to protect the supply of medicine and the welfare of our employees. Lilly does not source active pharmaceutical ingredients (API) for any of our approved medicines from China. U.S. pharmacies that temporarily don't have Lilly medicines in stock due to higher demand can order them from wholesalers, and generally they can be delivered in 1 to 2 days. Lilly has received a few reports of U.S. pharmacies stating that insulin orders are not being fulfilled due to "manufacturer backorder." Lilly has informed wholesalers and others in the supply chain that we do not have any products on backorder, including insulin. Patients should ask their pharmacist to secure an order from their wholesaler. With many individuals financially affected by the COVID-19 crisis, Lilly wants to remind people of cost-saving options for insulin, especially for those with no or limited income. Anyone who has lost employment and uses Lilly insulin should call the Lilly Diabetes Solution Center at (833) 808-1234 to learn about options that include access to free insulin that has been donated for people with lower incomes. For people with an urgent need for insulin and nowhere else to turn, the Solution Center can help provide immediate help. The Solution Center is open 9 am to 8 pm ET Monday through Friday. "COVID-19 is an unprecedented challenge for all of us, but Lilly has planned for such events," said Mike Mason, president, Lilly Diabetes. "Our manufacturing facilities, supply chain, and Lilly Diabetes Solution Center are designed to support those who rely on insulin. We are committed to providing a regular supply of safe insulin, and our Solution Center can provide real insulin affordability assistance for people during this difficult time, including people whose jobs have gone away. If you need help, please call the Lilly Diabetes Solution Center."

Da der er mange - selv inkluderet - der sveder fra børsen lige nu, kan det være rart med lige beskeder. Denne video gennemgår grundigt det drama, der foregår på markedet lige nu og giver klarhed over, hvad vi kan forvente i fremtiden, afhængigt af hvad der sker i fremtiden. Meget interessant og relevant for alle, der har investeret penge på børsen. Håber det hjælper dig. https://youtu.be/uYS2Gm1OXSY

10 High Quality A Rated Blue Chips with Low Debt to Buy Today https://www.youtube.com/watch?v=bZ3H33pGnAg FAST Graphs Analyze Out Loud Reviewing $ETN $ANTM $BLK $CMI $CSCO $GD $HON $MDT $MMM $UNH https://www.midgardfinance.com/tabulate/fastgraphs_2020-03-24.htm

Her lidt beregninger baseret på hvad vi kender af mulige peaksales m.m. Der er selvfølgelig lige en partneraftele eller 2 der skal på plads. Derudover skal data være iorder. Derfor også potentiel mulighed for mega kursfald såfremt p.aftale eller data fejler [image: 82000_Genmab_kurs_target_2024.JPG]

Jeg får dagligt spørgsmål, der går på, om vi dog ikke snart kan se bunden i aktiemarkedet. I denne video prøver jeg at give mit syn på verdens situation, samt viser hvilke tal, jeg holder øje med i min vurdering af, hvor markedet skal hen. I videoen kommer jeg både omkring aktier, Corona, kaossystemer, eksponentiel vækst osv. Se med her, hvis du vil høre min vurdering af situationen. https://www.youtube.com/watch?v=2KyHWjwygnc

Nu klogede vi os gevaldigt i forgårs om Danske Banks GF og udbytte. Minsandten om det ikke ser ud til, at aktien handles uden udbytte her til morgen. Enten er der sket en misforståelse på Københavns Fondsbørs, eller også er det korrekt. Altså at udbytte er gået fra. Det undrer mig bare at den handles hele tiden på kurs uden udbytte, og især at den stiger så meget. Det var da at håbe, at kursfastsættelse og udbyttefragang er korrekt - spørgsmålet er så, hvornår udbyttet betales! Men det hører vi nok mere om op ad formiddagen.

Er der risiko for at udbytte i morgen ikke bliver til noget?

Saa begynder der langsomt at dukke tal op med konsekvenserne af den noedvendige karantaene... Delta warns second-quarter revenue to fall $10 billion because of coronavirus https://www.cnbc.com/2020/03/20/delta-warns-second-quarter-revenue-to-fall-10-billion-because-of-coronavirus.html [image: 83073_DAL_quarterly_TTM_is.png] [image: 83073_venueFromContractWithCustomerExcludingAssessedTax_us_gaap.ProductOrService_us_gaap.AirlineDestinations_us_gaap.Passenger.png] [image: 83073_DAL_annual_is.png] [image: 83073_DAL_us_gaap.RevenueFromContractWithCustomerExcludingAssessedTax__.png]

Hej allesammen. Jeg vil gerne hjaelpe i disse tider. Det jeg er bedst til er data-analyse og -visualisering. Jeg har sat nedenstaaende side sammen, som maaske kan give et overblik over konsekvenserne af virus for forskellige US-virksomheder. Jeg har scannet diverse 8K-formularer fra SEC og fundet tekst-bidder om virus og markeret med roedt. Jeg ved ikke, om I kan bruge det til noget. Jeg haaber det. Det er bestemt ikke perfekt, men det var alt, hvad jeg kunne naa i loebet af en soendag eftermiddag. Det var ikke helt saa nemt, som jeg havde regnet med, paa grund af uhyrlig og forskellig-artet html-formatering. Der er baade falske positiver (ikke-relevant tekst inkluderet) og falske negativer (relevant tekst udelukket). Jeg bruger selv diverse RSS feeds fra f.eks. GlobeNewswire og filtrerer dem baseret paa diverse noegle-ord. http://midgardfinance.com/covid19/ Hos Finanstilsynet kan man desvaerre kun soege paa titel-feltet blandt meddelelser. Der er ikke saa mange danske boersnoterede virksomheder, saa maaske er det bare nemmest at foelge RSS feed og laese det hele, hvis man i stor grad er eksponeret mod danske aktier. Her et link til seneste dokumenter med intern viden: https://oasm.finanstilsynet.dk/dk/soegmeddelelseresultat.aspx?headline=&name=&RealAnnouncerCVR=&CVRnumber=&announcmentsId=&informationTypeId=10&languageId=-1&nationality=-1&AnnouncementTypeId=&pubDateFrom=2020-02-22 00:00&pubDateTo=2020-03-22 22:00&index=1&sindex=1 Her forsiden: https://oasm.finanstilsynet.dk/dk/forside.aspx Pas godt paa jer selv, jeres familie og jeres penge. God mandag

Af en eller anden årsag har en svensker besluttet at afhænde et betydeligt antal aktier, hmm ? Men .. her er vort udgangspunkt, såfremt vi kan forvente en "renovering" oven på korrektionen, graf: https://invst.ly/q6q4j Pt. ligger vi i en formation som vi formodentlig ville være brudt ud/op af, hvis ikke ENS havde været så flittig med at afhænde aktier. Køberne er spredt på flere. Hvilken strategi der ligger bag salget, tjaa, dit gæt er ligeså godt som mit. Alt lige fra tvangssalg hos en kunde til almindelig risikospredning. Formation: Macd på 15 min. chartet ser ud til at være på vej op, men den enerådende aktion fra ENS kan naturligvis få stor betydning på kort sigt. Det er ofte set før at større sælgere holder igen med salget den sidste time for at få et mere naturligt kursleje, men vi må se og håbe det bedste. mvh

Biotech/healthcare ser tilsyneladende stabil ud, men positiv tendens. Her et closeup på timebasis, graf: https://invst.ly/q6jef Og set i det større perspektiv på et dagschart: https://invst.ly/q6jh5 Så hvis du har holdt ud indtil nu, så er det nok ikke her du skal sælge, dog naturligvis afhængig af individuelle forhold, as usual ... Men kertelyset i tunnelen er nu blevet en kraftig lommelygte ! Hav en god dag ! mvh

Cheføkonomer udtaler: Massivt udsalg af statsobligationer vil gøre det dyrere at finansiere sin bolig. Dette kan resultere i lavere priser. Det er jo klart køberne der skal betale for hele gildet Ironi kan forekomme. Allerede d. 15/3 fik jeg meldinger om meget meget få handler og klart faldende priser. Nu er obligationskurserne for 0,5 % fastforrentet fladet med 10 kurspoint!!! Dette betyder markant dyrere at få finansieret sin bolig - hvis bank/realkredit vil være med

Vi har allerede en udbyttetråd for shipping-branchen 2020, men verden ligner ikke sig selv længere, og samtlige estimater m.v. er ikke meget værd pt. De bliver givetvis mindre end først antaget, men de bliver næppe helt fjernet. BW LPG og Avance må forventes at decimere deres udbytte betragteligt (helt fjerne dem?), mens crude oil tankers pt nok hæver dem, da de laver boksen, skønt kurserne ligger underdrejede. Jeg har kun kendskab til Hannisdahls estimater (som ikke just har ramt bulls eye i år), men hvad forventer I af ændringer i udbytte, og hvilke kilder bruger I? og the dark horse; hvad med tilbagekøb af aktier?